BioNTech (NASDAQ:BNTX) Stock Rating Reaffirmed by HC Wainwright

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $107.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 24.20% from the company’s current price.

BNTX has been the subject of several other research reports. The Goldman Sachs Group cut their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. UBS Group reduced their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. BMO Capital Markets dropped their target price on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a report on Thursday, March 21st. Finally, Oppenheimer assumed coverage on BioNTech in a research note on Friday, January 5th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, BioNTech presently has an average rating of “Hold” and a consensus price target of $120.40.

BioNTech Stock Performance

Shares of BNTX stock traded down $0.19 during mid-day trading on Wednesday, hitting $86.15. The stock had a trading volume of 1,063,601 shares, compared to its average volume of 668,485. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The firm has a market cap of $20.48 billion, a PE ratio of 20.91 and a beta of 0.23. BioNTech has a fifty-two week low of $85.21 and a fifty-two week high of $125.83. The company’s 50-day simple moving average is $91.67 and its 200-day simple moving average is $97.64.

BioNTech (NASDAQ:BNTX) last released its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. Sell-side analysts anticipate that BioNTech will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Harding Loevner LP acquired a new position in shares of BioNTech in the fourth quarter worth $410,984,000. Baillie Gifford & Co. increased its position in BioNTech by 15.5% during the 3rd quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock worth $934,612,000 after purchasing an additional 1,152,541 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in BioNTech by 4,861.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 972,535 shares of the company’s stock valued at $1,531,000 after purchasing an additional 952,932 shares during the last quarter. BlackRock Inc. lifted its holdings in BioNTech by 25.9% in the 1st quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock valued at $274,768,000 after purchasing an additional 331,101 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of BioNTech during the 1st quarter worth about $42,711,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.